Browse EX-10 agreements

REVOLVING CREDIT AGREEMENT

dated as of

July 28, 2026

among

ENTERPRISE PRODUCTS OPERATING LLC,

as Borrower

The Lenders Party Hereto

CITIBANK, N.A.,

as Administrative Agent

WELLS FARGO BANK, NATIONAL ASSOCIATION, JPMORGAN CHASE BANK, N.A., MIZUHO BANK, LTD., MUFG BANK, LTD., and TRUIST BANK,

as Co-Syndication Agents

BARCLAYS BANK PLC, ROYAL BANK OF CANADA,

SUMITOMO MITSUI BANKING CORPORATION,

THE BANK OF NOVA SCOTIA, HOUSTON BRANCH and

THE TORONTO-DOMINION BANK, NEW YORK BRANCH,

as Co-Documentation Agents

______________________________

CITIBANK, N.A., WELLS FARGO SECURITIES, LLC,

BARCLAYS BANK PLC, JPMORGAN CHASE BANK, N.A., MIZUHO BANK, LTD.,

MUFG BANK, LTD. RBC CAPITAL MARKETS,

SUMITOMO MITSUI BANKING CORPORATION,

TD SECURITIES (USA) LLC, THE BANK OF NOVA SCOTIA, and

TRUIST SECURITIES, INC.,

as Joint Lead Arrangers and Joint Bookrunners

$1,000,000,000 Revolving Credit Facility

---

TABLE OF CONTENTS

…

GUARANTY AGREEMENT

    THIS GUARANTY AGREEMENT, dated as of July 28, 2026, by ENTERPRISE PRODUCTS PARTNERS L.P., a Delaware limited partnership (the “Guarantor”), is in favor of CITIBANK, N.A., as Administrative Agent (the “Agent”) for the several lenders ( “Lenders”) that are or become parties to the Credit Agreement defined below.

WITNESSETH:

    WHEREAS, Enterprise Products Operating LLC (“Borrower”) has entered into that certain Revolving Credit Agreement of even date herewith among Borrower, Administrative Agent, and the Lenders party thereto (as the same may be amended, supplemented or otherwise modified from time to time, the “Credit Agreement”); and

    WHEREAS, one of the terms and conditions stated in the Credit Agreement for the making of the loans described therein is the execution and delivery to the Agent for the benefit of the Lenders of this Guaranty Agreement;

…

LIMITED WAIVER AND AMENDMENT NO. 3 TO FINANCING AGREEMENT

This LIMITED WAIVER AND AMENDMENT NO. 3 TO FINANCING AGREEMENT (this “Amendment”) dated as of July 29, 2026, is made by and among Accuray Incorporated, a Delaware corporation (the “Administrative Borrower”), the Guarantors party hereto, the Consenting Lenders (as defined below) party hereto, TCW Asset Management Company LLC, as Administrative Agent and Collateral Agent (together with its permitted successors in capacity as the administrative agent and the collateral agent, the “Administrative Agent”) and Wingspire Capital LLC, as Servicing Agent (in such capacity, including any successor thereto in such capacity, the “Servicing Agent”).

…

Execution Version

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of July 29, 2026, is by and among Accuray Incorporated, a Delaware corporation (the “Company”), and the investors identified on the Schedule of Investors attached hereto on Exhibit B (each, an “Investor” and, collectively, the “Investors”).

RECITALS

A.           The Company and the Investors are parties to, or lenders under, that certain Financing Agreement, dated as of June 6, 2025, as amended from time to time (the “Financing Agreement”).

…

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (this “Agreement”), effective as of July 23, 2026 (the “Effective Date”), is by and between NEXGEL, INC., a Delaware corporation (the “Company”), and Adam Levy, an individual (“Executive”). The Company and Executive shall sometimes be referred to herein individually as a “Party” and collectively as the “Parties”.

BACKGROUND

** **

**A. **Pursuant to the terms of this Agreement, the Company desires to continue to employ Executive as its President and Chief Executive Officer and Executive desires to continue to be employed by the Company as its President and Chief Executive Officer.

**B. **The Company and Executive were parties to that certain 2025 Executive Employment Agreement dated December 31, 2024 (the “Prior Agreement”). The Company and Executive acknowledge that the Prior Agreement has terminated pursuant to its terms and desire to enter into this Agreement to replace the Prior Agreement in its entirety, subject to the terms and conditions set forth herein.

AGREEMENT

** **

…

** **

Exhibit 10.1

** **

FUBOTV INC.

2020 EQUITY INCENTIVE PLAN

(As Amended and Restated Effective July 28, 2026)

1. Purposes of the Plan. The purposes of this Plan are:

	●	to attract and retain the best available personnel for positions of substantial responsibility,

	●	to provide additional incentive to Employees, Directors and Consultants, and

	●	to promote the success of the Company’s business.

…

** **

FORM OF REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 29, 2026 between HCW Biologics Inc., a Delaware corporation (the “Company”), and each purchaser appearing on the signature page to the Purchase Agreement (as defined below) (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

WHEREAS, the Company and the Purchasers are parties to that certain Securities Purchase Agreement, dated as of the date of this Agreement (the “Purchase Agreement”), pursuant to which the Purchasers are purchasing (i) shares of Common Stock (the “Shares”), (ii) Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”), and (iii) Common Stock Purchase Warrants (the “Common Warrants”) to purchase shares of Common Stock (the “Common Warrant Shares” and together with the Pre-Funded Warrant Shares, the “Warrant Shares”) of the Company; and

…

** **

FORM OF SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of July 29, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

RECITALS

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and other securities of the Company as more fully described in this Agreement;

…

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of July __, 2026, is by and among Onconetix, Inc., a Delaware corporation with offices located at 201 E. Fifth Street, Suite 1900 Cincinnati, OH 45202 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

RECITALS

A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the 1933 Act.

…

REGISTRATION RIGHTS AGREEMENT

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 28, 2026, is by and between [__________] a [__________] (the “Investor”), and Onconetix, Inc., a Delaware corporation (the “Company”).

RECITALS

A. The Company and the Investor have entered into that certain Common Stock Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Company may issue to the Investor, from time to time, up to the lesser of (a) $750,000,000 and (b) 19.99% of the Company’s outstanding common stock, par value $0.00001 per share (the “Common Stock”) as of the date of this Agreement, unless shareholder approval is obtained to issue more than such 19.99%.

…

COMMON STOCK PURCHASE AGREEMENT

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of July 28, 2026 (this “Agreement”), by and among [_______________], a [______________] (the “Investor”), and Onconetix, Inc., a Delaware corporation (the “Company”).

RECiTALS

WHEREAS, the parties desire that, upon the terms and subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to the lesser of (a) $750,000,000 and (b) 19.99% of the Company’s outstanding shares of Common Stock as of the date of this Agreement (to the extent applicable under Section 2.4 hereof), unless (i) stockholder approval is obtained to issue more than such 19.99% (“Stockholder Approval”) or (ii) the price of applicable sales of Common Stock to the Investor under this Agreement equals or exceeds the lower of (A) the official Closing Sale Price on the Nasdaq Capital Market or any nationally recognized succes

…

REGISTRATION RIGHTS AGREEMENT

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of ___, 2026, is by and among Onconetix, Inc., a Delaware corporation with offices located at 201 E. Fifth Street, Suite 1900 Cincinnati, OH 45202 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).

RECITALS

A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of [___], 2026 (the “Securities Purchase Agreement”), the Company has agreed, upon the terms and subject to the conditions of the Securities Purchase Agreement, to issue and sell to each Buyer shares of the Company’s Series F Convertible Preferred Stock, par value $0.00001 per share (the “Series F Preferred Stock”), which will be convertible into shares (the “Conversion Shares”) of common stock of the Company, $0.00001 par value per share (the “Common Stock”) in accordance with the terms of the Certificate of Designations (as defined in the Securities Purchase Agreement).

…